SpringerLink
Log in

Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases

  • Case Report
  • Published:
Modern Rheumatology

Abstract

Intravenous cyclophosphamide pulse therapy (IVCY) exerts its efficacy against interstitial lung disease (ILD) associated with systemic sclerosis (SSc) by restoring vascular injuries as well as aberrant immune activation. We recently experienced two patients with SSc-ILD in whom the values of brachial flow-mediated dilation (FMD) reflected the efficacy of IVCY. We herein report the details of these cases and discuss the potential of FMD to predict and evaluate the effect of IVCY on SSc-ILD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev. 2003;2:181–91.

    Article  PubMed  CAS  Google Scholar 

  2. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol. 2000;12:527–33.

    Article  PubMed  CAS  Google Scholar 

  3. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin N Am. 1996;22:675–94.

    Article  CAS  Google Scholar 

  4. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheumatology (Oxford). 2010;49(12):2375–80.

    Article  CAS  Google Scholar 

  5. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–5.

    Article  PubMed  CAS  Google Scholar 

  6. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314–9.

    Article  PubMed  CAS  Google Scholar 

  7. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56:1985–93.

    Article  PubMed  CAS  Google Scholar 

  8. Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis. 2010;69:319–24.

    Article  PubMed  CAS  Google Scholar 

  9. Worda M, Sgonc R, Dietrich H, Niederegger H, Sundick RS, Gershwin ME, et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum. 2003;48:2605–14.

    Article  PubMed  CAS  Google Scholar 

  10. Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998;101:2029–35.

    Article  PubMed  CAS  Google Scholar 

  11. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43:2550–62.

    Article  PubMed  CAS  Google Scholar 

  12. Wusirika R, Ferri C, Marin M, Knight DA, Waldman WJ, Ross P Jr, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol. 2003;120:596–606.

    Article  PubMed  CAS  Google Scholar 

  13. Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y, et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol. 2005;174:5740–9.

    PubMed  CAS  Google Scholar 

  14. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98:785–92.

    Article  PubMed  CAS  Google Scholar 

  15. Parra ER, Aguiar AC Jr, Teodoro WR, de Souza R, Yoshinari NH, Capelozzi VL. Collagen V and vascular injury promote lung architectural changes in systemic sclerosis. Clin Respir J. 2009;3:135–42.

    Article  PubMed  CAS  Google Scholar 

  16. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev. 2011;10:248–55.

    Article  PubMed  Google Scholar 

  17. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007;66:940–4.

    Article  PubMed  Google Scholar 

  18. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–66.

    Article  PubMed  CAS  Google Scholar 

  19. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–70.

    Article  PubMed  CAS  Google Scholar 

  20. Mouthon L, Berezne A, Guillevin L, Valeyre D. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir Med. 2010;104(Suppl 1):S59–69.

    Article  PubMed  Google Scholar 

  21. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2:679–85.

    Article  PubMed  CAS  Google Scholar 

  22. Casale R, Generini S, Luppi F, Pignone A, Matucci-Cerinic M. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud’s phenomenon) in a case of early systemic sclerosis. Arthritis Rheum. 2004;51:665–9.

    Article  PubMed  Google Scholar 

  23. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum. 2003;48:2256–61.

    Article  PubMed  CAS  Google Scholar 

  24. Caramaschi P, Volpe A, Pieropan S, Tinazzi I, Mahamid H, Bambara LM, et al. Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. Clin Rheumatol. 2009;28:391–5.

    Article  PubMed  Google Scholar 

  25. Rollando D, Bezante GP, Sulli A, Balbi M, Panico N, Pizzorni C, et al. Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol. 2010;37:1168–73.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Takehiro Takahashi, Yoshihide Asano, Zenshiro Tamaki, Takashi Taniguchi, Yohei Ichimura, Tetsuo Toyama & Shinichi Sato

  2. Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Eisuke Amiya, Masaru Hatano, Atsuko Ozeki, Aya Watanabe, Shuichi Kawarasaki, Tomoko Nakao, Masafumi Watanabe, Yasunobu Hirata & Ryozo Nagai

Authors
  1. Takehiro Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihide Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eisuke Amiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaru Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zenshiro Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsuko Ozeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aya Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuichi Kawarasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoko Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yohei Ichimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tetsuo Toyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Masafumi Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasunobu Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ryozo Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shinichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihide Asano.

About this article

Cite this article

Takahashi, T., Asano, Y., Amiya, E. et al. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Mod Rheumatol 22, 598–601 (2012). https://doi.org/10.1007/s10165-011-0545-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-011-0545-1

Keywords

Search

Navigation